IMI2 - Call 15

IMI2 - Call 15 was launched on 18 July 2018 with the following topics:

  • Integrated research platforms enabling patient-centric drug development
  • Blockchain Enabled Healthcare
  • Microenvironment imposed signatures in tissue and liquid biopsies in immune-mediated diseases
  • Emerging translational safety technologies and tools for interrogating human immuno-biology
  • Development and validation of translational platforms in support of synaptopathy drug discovery
  • Digital endpoints in neurodegenerative and immune-mediated diseases

Topics under the IMI2 Antimicrobial Resistance (AMR) Accelerator programme

  • AMR Accelerator programme Pillar A: Capability Building Network to accelerate and validate scientific discoveries
  • AMR Accelerator programme Pillar B: Tuberculosis drug development network to accelerate and validate scientific discoveries and advance the R&D pipeline of new and innovative agents to address the global tuberculosis epidemic

More information on the topics can be found in IMI's press release and in the Call text. Other relevant documents can be found on the IMI2 Call documents page.


The projects resulting from IMI2 - Call 15 are:

  • COMBINE - Collaboration for prevention and treatment of MDR bacterial infections
    factsheet | website
  • ERA4TB - European Regimen Accelerator for Tuberculosis
    factsheet | website
  • EU-PEARL - EU patient-centric clinical trial platform
    factsheet | website
  • IDEA-FAST - Identifying digital endpoints to assess fatigue, sleep and activities in daily living in neurodegenerative disorders and immune-mediated inflammatory diseases
    factsheet | website
  • ImmUniverse - Better control and treatment of immune-mediated diseases by exploring the universe of microenvironment imposed tissue signatures and their correlates in liquid biopsies
    factsheet | website
  • imSAVAR - Immune safety avatar: nonclinical mimicking of the immune system effects of immunomodulatory therapies
    factsheet | website
  • PharmaLedger - PharmaLedger
    factsheet | website

Call statistics

  • Proposals submitted: 42
  • Inadmissible & ineligible proposals: 3
  • Proposals recommended for funding: 7
  • Proposals not recommended for funding: 1